Up to $818 million deal between J&J and Locus Biosciences points to a new path for CRISPR therapies

The approximately $818 million offer in between Locus Biosciences and Janssen Pharmaceuticals (a department of Johnson &&Johnson) that was revealed the other day points towards a brand-new course for CRISPR gene modifying innovations and (possibly) the entire field of microbiome-targeted treatments. Based in Research Triangle Park, N.C., Locus is advertising...
Read more